Meet our SPARK Fellows

Introducing Cohort 8

Traci Lyons, PhD

Development of a Novel SEMA7A Targeted Therapy to Treat Cancer

Development of a Novel SEMA7A Targeted Therapy to Treat Cancer

We propose developing a humanized SEMA7A-targeted antibody (SmAbH1) as a novel breast cancer treatment. Our mouse monoclonal antibody has shown promising results, promoting full tumor regression in about 60% of tested animals, especially when the immune system is intact. We have also demonstrated its effectiveness in reducing metastasis in mice. The recombinant version (rSmAbH1) binds more effectively to SEMA7A, and we are ramping up manufacturing for further in vivo studies. In our project, we’ll conduct in vivo proof-of-concept studies, humanize rSmAbH1, and test the humanized antibodies in our models.

Learn more about Dr. Lyons

Cohort 7

Jessica Rove, MD

Jessica Rove, MD

Colorado Chest Tube

Juan-Pablo Idrovo, MD

Juan-Pablo Idrovo, MD

Gastrostomy Tube Guardian

Rui Zhao, PhD

Rui Zhao, PhD

Developing a First-in-Class Allosteric Eya2 Tyrosine Phosphatase Inhibitor for Brain Cancer Therapy

Sujatha Venkataraman, PhD

Development of Gated Dual-antigen Targeting CAR-T Cell Therapy to Treat ATRT, an Aggressive Brain Tumor in Children

zhirui_wang_500

Zhirui Wang, PhD

Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia and Other CD47+ Cancers

Cohort 6

Traci Lyons, PhD

Development of a Novel SEMA7A Targeted Therapy to Treat Cancer

Development of a Novel SEMA7A Targeted Therapy to Treat Cancer

We propose developing a humanized SEMA7A-targeted antibody (SmAbH1) as a novel breast cancer treatment. Our mouse monoclonal antibody has shown promising results, promoting full tumor regression in about 60% of tested animals, especially when the immune system is intact. We have also demonstrated its effectiveness in reducing metastasis in mice. The recombinant version (rSmAbH1) binds more effectively to SEMA7A, and we are ramping up manufacturing for further in vivo studies. In our project, we’ll conduct in vivo proof-of-concept studies, humanize rSmAbH1, and test the humanized antibodies in our models.

Learn more about Dr. Lyons

Cohort 5

Traci Lyons, PhD

Development of a Novel SEMA7A Targeted Therapy to Treat Cancer

Development of a Novel SEMA7A Targeted Therapy to Treat Cancer

We propose developing a humanized SEMA7A-targeted antibody (SmAbH1) as a novel breast cancer treatment. Our mouse monoclonal antibody has shown promising results, promoting full tumor regression in about 60% of tested animals, especially when the immune system is intact. We have also demonstrated its effectiveness in reducing metastasis in mice. The recombinant version (rSmAbH1) binds more effectively to SEMA7A, and we are ramping up manufacturing for further in vivo studies. In our project, we’ll conduct in vivo proof-of-concept studies, humanize rSmAbH1, and test the humanized antibodies in our models.

Learn more about Dr. Lyons

Cohort 4

Cohort 3

Cohort 2

Cohort 1

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-3720

CMS Login